Role of MnSOD gene polymorphism and Type II diabetes mellitus

Sathish Kumar. Research Scholar, Malwanchal University.

Prof.Dr. Jaya Jain ,Research Supervisor, Malwanchal University

Introduction

Diabetes type II is a persistent metabolic disorder that impacts the lives of millions of people all over the world. Insulin resistance, impaired glucose metabolism, and an increased risk of cardiovascular disease are all symptoms that are associated with this condition. The onset of Type II diabetes can be attributed to a number of factors, including genetics, lifestyle choices, and environmental factors. In recent years, there has been a growing interest in the role that genetic factors play in the development of Type II diabetes. This growing interest includes the role that MnSOD gene polymorphism plays in the disease.

MnSOD, or manganese superoxide dismutase, is an antioxidant enzyme that is extremely important in the process of shielding cells from the damaging effects of oxidative stress. The MnSOD gene, which can be found on chromosome 6q25.3, is responsible for its encoding. A polymorphism in the MnSOD gene has been shown to have an effect on the activity of the MnSOD enzyme, which suggests that it may play a role in the development of Type II diabetes. In this article, we will discuss the role that MnSOD gene polymorphism plays in Type II diabetes as well as its potential implications for diagnosis, treatment, and prevention of the disease.

Polymorphism of the MnSOD Gene

Variations in the DNA sequence of the MnSOD gene that have an effect on the activity of the MnSOD enzyme are referred to as polymorphisms of the MnSOD gene. A single nucleotide polymorphism (SNP) that is found in the promoter region of the MnSOD gene is the type of MnSOD gene polymorphism that occurs the most frequently. This particular SNP is referred to as rs4880, and it causes an alteration in the MnSOD protein by changing the amino acid at position 16 from alanine to valine. It has been demonstrated that the variant with the valine amino acid has a lower MnSOD activity than the variant with the alanine amino acid, which results in an increased susceptibility to oxidative stress.

The association between MnSOD gene polymorphism and Type II diabetes has been the subject of investigation in a number of studies. The MnSOD rs4880 polymorphism was found to be significantly associated with an increased risk of Type II diabetes, according to the findings of a meta-analysis that included 18 studies with a total of 4,803 cases and 5,129 controls. When compared to the alanine allele, the valine allele was found to be associated with a 16% increased risk of developing Type II diabetes. The MnSOD rs4880 polymorphism was found to have a significant association with Type II diabetes in a further meta-analysis that comprised 22 studies and included 8,206 cases and 9,350 controls. When compared to the alanine allele, the valine allele was found to be associated with a 21% higher likelihood of developing Type II diabetes.

The Role of MnSOD Gene Polymorphism in the Development of Type II Diabetes Mechanisms

We do not yet have a complete understanding of the mechanisms that underlie the association between the MnSOD gene polymorphism and Type II diabetes. Nevertheless, there have been a number of hypotheses put forward. First, the reduced activity of MnSOD that is associated with the valine variant may result in increased oxidative stress, which may play a role in the development of insulin resistance as well as impaired glucose metabolism. It has been demonstrated that oxidative stress can disrupt insulin signalling and glucose uptake in skeletal muscle and adipose tissue, both of which are essential for maintaining normal glucose levels in the blood.

Second, a polymorphism in the MnSOD gene may disrupt the function of beta cells in the pancreas, which are the cells that are accountable for the production and secretion of insulin. It has been demonstrated that MnSOD protects beta cells from the damaging effects of oxidative stress and increases insulin secretion. The reduced activity of MnSOD that is associated with the valine variant may contribute to the development of Type II diabetes by causing beta cell dysfunction and impaired insulin secretion.

Third, there is a possibility that the MnSOD gene polymorphism interacts with other genetic factors as well as environmental ones to raise the risk of Type II diabetes. For instance, one study found that the association between the MnSOD rs4880 polymorphism and Type II diabetes was stronger in people who had a high body mass index (BMI) compared to those who had a low BMI. This was the case for both individuals with and without the polymorphism. Oxidative stress has been shown to play a role in the development of obesity-related metabolic disorders, which is a well-established risk factor for type II diabetes. Obesity is a well-established risk factor for type II diabetes.

In addition, the MnSOD gene polymorphism may interact with other genetic factors, such as polymorphisms in genes related to insulin signalling and glucose metabolism, to increase the risk of developing type II diabetes.

Consequences for the Diagnosis, Treatment, and Prevention of the Condition

The fact that a polymorphism in the MnSOD gene is associated with Type II diabetes may have diagnostic, therapeutic, and preventative repercussions. First, a polymorphism in the MnSOD gene might be able to act as a biomarker for the likelihood of developing Type II diabetes. Screening for the MnSOD gene polymorphism could identify individuals who are at an increased risk of developing Type II diabetes, allowing for early intervention and prevention strategies to be implemented.

Second, a polymorphism in the MnSOD gene might affect how well a patient with Type II diabetes responds to treatment. Because antioxidant therapies, such as vitamin E and C supplements, have the potential to reduce oxidative stress and improve insulin sensitivity, they have been suggested as possible treatments for type II diabetes. On the other hand, the presence of a particular polymorphism in the MnSOD gene may affect how effective these treatments are. People who have the valine variant of the gene may have a better response to antioxidant therapies than those who have the alanine variant.

Third, the MnSOD gene polymorphism may point to potential new treatment targets for the development of innovative Type II diabetes medications. For instance, medications that boost MnSOD activity may protect against oxidative stress and improve insulin sensitivity in people who have a particular gene variant for MnSOD.

Conclusion

In conclusion, MnSOD gene polymorphism is associated with an increased risk of Type II diabetes, possibly through mechanisms involving increased oxidative stress and impaired insulin secretion and signalling. This association was found in a study that was conducted in China. The fact that a polymorphism in the MnSOD gene is associated with Type II diabetes may have diagnostic, therapeutic, and preventative repercussions.

Screening for the MnSOD gene polymorphism could identify individuals who are at an increased risk of developing Type II diabetes, allowing for early intervention and prevention strategies to be implemented. In addition, the MnSOD gene polymorphism may have an effect on how well a patient responds to treatment for Type II diabetes and may also suggest new treatment targets. A deeper understanding of the mechanisms that underlie the association between MnSOD gene polymorphism and Type II diabetes as well as the development of personalised strategies for the prevention and treatment of this complex metabolic disorder requires additional research.

Reference

1. Naghibi M, Mojahedi MJ, Jarrahi L, Emadzadeh A, Ahmadi R, Emadzadeh M, Taraz Jamshidi S, Bahri N. Prevalence of chronic kidney disease and its risk factors in Gonabad, Iran. Iran J Kidney Dis. 2015;9:449–453. [PubMed] [Google Scholar]

2. Betonico CC, Titan SM, Correa-Giannella ML, Nery M, Queiroz M. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. Clinics (Sao Paulo) 2016;71:47–53. doi: 10.6061/clinics/2016(01)08. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73–81. doi: 10.1038/nrneph.2015.173. [PubMed] [CrossRef] [Google Scholar]

4. Pourvali K, Abbasi M, Mottaghi A. Role of superoxide dismutase 2 gene Ala16Val polymorphism and Total antioxidant capacity in diabetes and its complications. Avicenna J Med Biotechnol. 2016;8:48–56. [PMC free article] [PubMed] [Google Scholar]

5. Satyavani K, Kothandan H, Jayaraman M, Viswanathan V. Direct costs associated with chronic kidney disease among type 2 diabetic patients in India. Indian J Nephrol. 2014;24:141–147. doi: 10.4103/0971-4065.132000. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Jiang G, Hu C, Tam CH, Lau ES, Wang Y, Luk AO, Yang X, Kong AP, Ho JS, Lam VK, et al. Genetic and clinical variables identify predictors for chronic kidney disease in type 2 diabetes. Kidney Int. 2016;89:411–420. doi: 10.1016/j.kint.2015.09.001. [PubMed] [CrossRef] [Google Scholar]

7. Banerjee M, Vats P. Reactive metabolites and antioxidant gene polymorphisms in type 2 diabetes mellitus. Redox Biol. 2013;2C:170–177. [PMC free article] [PubMed] [Google Scholar]

8. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–373. doi: 10.1016/j.biopha.2005.07.002. [PubMed] [CrossRef] [Google Scholar]

9. Lee SJ, Choi MG. Association of manganese superoxide dismutase gene polymorphism (V16A) with diabetic macular edema in Korean type 2 diabetic patients. Metabolism. 2006;55:1681–1688. doi: 10.1016/j.metabol.2006.08.011. [PubMed] [CrossRef] [Google Scholar]

10. Bendlova B, Vejrazkova D, Vcelak J, Lukasova P, Burkonova D, Kunesova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M. PPAR [gamma] 2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2. Physiol Res. 2008;57:S77. [PubMed] [Google Scholar]

11. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9:6–22. doi: 10.1900/RDS.2012.9.6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Landrum MJLJ, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, Maddipatla Z, Malheiro A, McDaniel K, Ovetsky M, Riley G, Zhou G, Holmes JB, Kattman BL, Maglott DR. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018; [PMC free article] [PubMed]